Hemoglobin A1c Threshold for Reduction in Bone Turnover in Men With Type 2 Diabetes Mellitus

Emerging data suggest that type 2 diabetes mellitus (T2D) is associated with an increased risk for fractures despite relatively normal or increased bone mineral density (BMD). Although the mechanism for bone fragility in T2D patients is multifactorial, whether glycemic control is important in genera...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2021-12, Vol.12, p.788107-788107
Main Authors: Joad, Sabaa, Ballato, Elliot, Deepika, Fnu, Gregori, Giulia, Fleires-Gutierrez, Alcibiades Leonardo, Colleluori, Georgia, Aguirre, Lina, Chen, Rui, Russo, Vittoria, Fuenmayor Lopez, Virginia Carolina, Qualls, Clifford, Villareal, Dennis T, Armamento-Villareal, Reina
Format: Article
Language:English
Subjects:
Absorptiometry, Photon - methods
Adult
Aged
Biomarkers - blood
Bone Density - physiology
Bone Remodeling - physiology
bone turnover markers
Cross-Sectional Studies
CTX
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - diagnostic imaging
Diabetes Mellitus, Type 2 - epidemiology
Endocrinology
Glycated Hemoglobin A - metabolism
Hemoglobin A1c
Humans
Hypogonadism - blood
Hypogonadism - diagnostic imaging
Hypogonadism - epidemiology
Male
Middle Aged
osteocalcin
type 2 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Emerging data suggest that type 2 diabetes mellitus (T2D) is associated with an increased risk for fractures despite relatively normal or increased bone mineral density (BMD). Although the mechanism for bone fragility in T2D patients is multifactorial, whether glycemic control is important in generating this impairment in bone metabolism remains unclear. The purpose of our study is to identify a hemoglobin A1c (A1c) threshold level by which reduction in bone turnover begins in men with T2D. A cross-sectional analysis of baseline data was obtained from 217 men, ages 35-65, regardless of the presence or absence of hypogonadism or T2D, who participated in 2 clinical trials. The following data were obtained: A1c by HPLC, testosterone and estradiol by LC/MS, bone turnover markers Osteocalcin [OC], C-terminal telopeptide [CTx], and sclerostin by ELISA, and BMD by DXA. Patients were grouped into 4 categories based of A1c (group I:
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2021.788107